Requires Infectious Disease consultation for use OR completion of the Restricted Antimicrobial order form for approved indications Endocarditis or bloodstream infection 6-10mg/kg IV every 24 hr Skin and soft tissue infections 4mg/kg IV every 24 hr
Unknown for severe hepatic dysfunction
Endocarditis or bacteremia caused by MRSA in a patient with a serious allergy to vancomycin
Therapy for MRSA infections (other than penumonia) in which the MIC of vancomycin is ≥ 2 mcg/ml
Endocarditis or bacteremia caused by MRSA in a patient failing therapy with vancomycin (defined as decompensation after 3-4 days of therapy, or failure to clear blood cultures after 7-9 days despite adeqaute vancomycin levels)
Therapy for VRE infections (other than pneumonia) when pathogen is resistant to linezolid
Treatment of pneumonia, as daptomycin is inactivated by pulmonary surfactant
Empiric therapy for gram positive infections
VRE colonization of the urine, respiratory tract, or wounds.
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC ≥ 2) and VRE including endovascular infection
weekly creatinine kinase
Muscle pain or weakness
GI side effects common
Myopathy including rhabdomyolysis
Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.
Higher doses used for endovascular infection.
Recommend Infectious Disease Consult.
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.
Antimicrobial class: Cyclic Lipopeptide.
Pregnancy category: B
Average serum half life: 9 hours
Urine penetration: Therapeutic
Lung penetration: Poor
CSF penetration: Poor